Compounds > terfenadine
Page last updated: 2024-08-16

terfenadine and lovastatin

terfenadine has been researched along with lovastatin in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's4 (33.33)29.6817
2010's6 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Belas, F; Chaudhary, AK; Cvetkovic, M; Dempsey, PJ; Fromm, MF; Kim, RB; Leake, B; Roden, DM; Roden, MM; Wandel, C; Wilkinson, GR; Wood, AJ1
Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ekins, S; Williams, AJ; Xu, JJ1
Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL1
Harris, RZ; Tsunoda, SM1
Ebert, SN; Katchman, AN; Koerner, J; Tosaka, T; Woosley, RL1

Other Studies

12 other study(ies) available for terfenadine and lovastatin

ArticleYear
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
    Pharmaceutical research, 1999, Volume: 16, Issue:3

    Topics: Animals; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Resistance, Multiple; Enzyme Inhibitors; Humans; Male; Mice; Oxidoreductases, N-Demethylating; Pharmacokinetics; Substrate Specificity

1999
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
    Biochemical and biophysical research communications, 2001, Nov-30, Volume: 289, Issue:2

    Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors

2001
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:5

    Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine

2012
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
    PloS one, 2016, Volume: 11, Issue:10

    Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat

2016
Timing of drug administration to prevent drug interactions.
    JAMA, 1996, Feb-14, Volume: 275, Issue:6

    Topics: Anticholesteremic Agents; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Histamine H1 Antagonists; Lovastatin; Terfenadine

1996
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
    The Journal of pharmacology and experimental therapeutics, 2006, Volume: 316, Issue:3

    Topics: Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Electrocardiography; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Haloperidol; Humans; Loratadine; Lovastatin; Methadone; Oxides; Pentamidine; Potassium Channel Blockers; Rabbits; Terfenadine; Torsades de Pointes

2006